[go: up one dir, main page]

MX2010007956A - Analogos de 13,13-dimetil-des-c,d de compuestos de 1a,25-dihidroxi-19-nor-vitamina d3 y formas de dosificacion de composicion topica y metodos de tratamiento de condiciones de la piel. - Google Patents

Analogos de 13,13-dimetil-des-c,d de compuestos de 1a,25-dihidroxi-19-nor-vitamina d3 y formas de dosificacion de composicion topica y metodos de tratamiento de condiciones de la piel.

Info

Publication number
MX2010007956A
MX2010007956A MX2010007956A MX2010007956A MX2010007956A MX 2010007956 A MX2010007956 A MX 2010007956A MX 2010007956 A MX2010007956 A MX 2010007956A MX 2010007956 A MX2010007956 A MX 2010007956A MX 2010007956 A MX2010007956 A MX 2010007956A
Authority
MX
Mexico
Prior art keywords
dihydroxy
analogs
dimethyl
compounds
methods
Prior art date
Application number
MX2010007956A
Other languages
English (en)
Inventor
Margaret Clagett-Dame
Lori A Plum
Hector F Deluca
Rafael R Sicinski
Pawel Grzywacz
Katarzyna Plonska-Ocypa
Nirca J Nieves
Original Assignee
Wisconsin Alumni Reasearch Fou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Reasearch Fou filed Critical Wisconsin Alumni Reasearch Fou
Publication of MX2010007956A publication Critical patent/MX2010007956A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen análogos de 13,13-dimetil-flfes-C,D de compuestos de 1a,25-dihidroxi-19-nor-vitamina D3 y formas de dosificación de composición tópica de los mismos, y métodos para tratar condiciones de la piel de los mismos. Los ejemplos de ingredientes farmacéuticos activos incluyen (1R, 3R)-5-[(E)-(S)-11'-hidroxi-5',5',7',11'-tetrametil-dodec-2'-enili den]-2-metilen-ciclohexano-1,3-diol, (1R,3R)-5-[(Z)-(S)-11'-hidrox i-5',5',7',11'-tetrametil-dodec-2'-eniliden]-2-metilen-ciclohexan o-1,3-diol, (1R,3R)-5-[(E)-(R)-11'-hidroxi-5',5',7',11'-tetrametil -dodec-2'-eniliden]-2-metilen-ciclohexano-1,3-diol, y (1R,3R)-5-[(Z)-(R)-11'-hidroxi-5',5',7',11'-tetrametil-dodec-2'-e niliden]-2-metilen-ciclohexano-1,3-diol.
MX2010007956A 2008-01-22 2009-01-22 Analogos de 13,13-dimetil-des-c,d de compuestos de 1a,25-dihidroxi-19-nor-vitamina d3 y formas de dosificacion de composicion topica y metodos de tratamiento de condiciones de la piel. MX2010007956A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2269608P 2008-01-22 2008-01-22
PCT/US2009/031663 WO2009094426A1 (en) 2008-01-22 2009-01-22 13.13-dimethyl-des-c,d analogs of 1alpha, 25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions

Publications (1)

Publication Number Publication Date
MX2010007956A true MX2010007956A (es) 2010-09-14

Family

ID=40430329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007956A MX2010007956A (es) 2008-01-22 2009-01-22 Analogos de 13,13-dimetil-des-c,d de compuestos de 1a,25-dihidroxi-19-nor-vitamina d3 y formas de dosificacion de composicion topica y metodos de tratamiento de condiciones de la piel.

Country Status (7)

Country Link
US (1) US8193171B2 (es)
EP (1) EP2247563A1 (es)
JP (1) JP2011510088A (es)
AU (1) AU2009206449B2 (es)
CA (1) CA2712748A1 (es)
MX (1) MX2010007956A (es)
WO (1) WO2009094426A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007298651A1 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
CA2712748A1 (en) 2008-01-22 2009-07-30 Wisconsin Alumni Reasearch Foundation 13,13-dimethyl-des-c,d analogs of 1.alpha.,25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
CN1103755C (zh) * 1993-07-09 2003-03-26 桑拉米克斯实验公司 维生素ｄ的新型结构类似物
US6392071B1 (en) 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
AU7653998A (en) * 1997-05-23 1998-12-11 F. Hoffmann-La Roche Ag Cyclohexanediol derivatives
US6184422B1 (en) 1998-02-26 2001-02-06 Hoffman-La Roche Inc. Cyclohexanediol derivatives
ES2533719T3 (es) * 2005-08-30 2015-04-14 Wisconsin Alumni Research Foundation Análogos Des-C,D de 1alfa,25-dihidroxi-19-norvitamina D3
CA2712748A1 (en) 2008-01-22 2009-07-30 Wisconsin Alumni Reasearch Foundation 13,13-dimethyl-des-c,d analogs of 1.alpha.,25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof

Also Published As

Publication number Publication date
WO2009094426A1 (en) 2009-07-30
AU2009206449A1 (en) 2009-07-30
AU2009206449B2 (en) 2014-04-24
US8193171B2 (en) 2012-06-05
US20090186950A1 (en) 2009-07-23
WO2009094426A8 (en) 2010-09-02
EP2247563A1 (en) 2010-11-10
JP2011510088A (ja) 2011-03-31
CA2712748A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
BRPI0918337A2 (pt) composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso
MX2009013989A (es) Terapia en combinacion para depresion.
EA201100305A1 (ru) Лечение респираторных заболеваний
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
WO2007143607A3 (en) Method of treating atrophic vaginitis
RU2010107892A (ru) Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их
CL2009002183A1 (es) Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014011981A2 (pt) formulações farmacêuticas
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
MX2009012472A (es) Combinacion que comprende acido pirrolidona-5-carboxilico y por lo menos un compuesto de citrulina, arginina y asparragina, y su uso en el tratamiento de dermatitis atopica.
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200639159A (en) Treatment of pain
PH12013500371A1 (en) Therapeutic agent for pain
WO2013062442A3 (ru) Композиция для лечения рассеянного склероза (варианты)
DE602004018647D1 (de) Galloylpeptide

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration